Baloxavir Marboxil
Single-dose oral treatment and post-exposure prophylaxis of influenza A and B
- CAS No.
- 1985606-14-1
- Indication Class
- Anti-infectives
- Patent Expiry
- Expiring in 3-5 yrs · 2031 (indicative)
- Therapeutic Area
- Anti-infective / Antiviral
- Labeled Purity
- 98%+
- Registration Readiness
- GMP/DMF
- Commercialization Tier
- API (Commercialized)
- Linked Intermediates
- 4 key intermediates available
- Patent Scope
- Compound patent in major markets
Key Intermediates for This API
Order: listed intermediates that accept enquiries first; fragments shared across several APIs rank higherListing Logic · Why It's Worth Listing
A novel single-oral-dose influenza agent with concentrated seasonal demand; integrated API-to-finished supply is attractive for regional pandemic stockpiling.
Anti-infective / Antiviral · Marketed; available for immediate sourcing
GMP/DMF-ready; supports regulatory filing and audit in target markets
4 key intermediates available; scale-up and cost control manageable
Data File Pack
Product Description
Baloxavir marboxil is an oral antiviral medication used for the treatment of acute, uncomplicated influenza (flu) in adults and children.
Supply source: Unibest · Baloxavir Marboxil, sourced, vetted and delivered by Unibest. Therapeutic area, indication and listing rationale are qualitative summaries based on public drug knowledge for business reference; actual registration availability and quality specifications are subject to DMF/GMP documentation and the technical agreement confirmed at order.